Blau Farmaceutica SA
BOVESPA:BLAU3
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.2736
17
|
Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BLAU3 stock under the Base Case scenario is 23.42 BRL. Compared to the current market price of 14.82 BRL, Blau Farmaceutica SA is Undervalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Blau Farmaceutica SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BLAU3 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Blau Farmaceutica SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Blau Farmaceutica SA
Balance Sheet Decomposition
Blau Farmaceutica SA
Current Assets | 1.6B |
Cash & Short-Term Investments | 431.9m |
Receivables | 601.9m |
Other Current Assets | 552.1m |
Non-Current Assets | 1.7B |
Long-Term Investments | 265.2m |
PP&E | 800.4m |
Intangibles | 447m |
Other Non-Current Assets | 143m |
Current Liabilities | 455.8m |
Accounts Payable | 219.5m |
Accrued Liabilities | 112.2m |
Other Current Liabilities | 124.1m |
Non-Current Liabilities | 688.5m |
Long-Term Debt | 483.5m |
Other Non-Current Liabilities | 205m |
Earnings Waterfall
Blau Farmaceutica SA
Revenue
|
1.7B
BRL
|
Cost of Revenue
|
-1.1B
BRL
|
Gross Profit
|
596.5m
BRL
|
Operating Expenses
|
-330.6m
BRL
|
Operating Income
|
265.9m
BRL
|
Other Expenses
|
-78.9m
BRL
|
Net Income
|
187m
BRL
|
Free Cash Flow Analysis
Blau Farmaceutica SA
BRL | |
Free Cash Flow | BRL |
Blau achieved record revenue of BRL 465 million in Q2 '24, up from BRL 387 million in Q4 '23, driven by a resilient pharmaceutical market. Key initiatives included speeding up market entry across three business units and acquiring Bergamo, which boosted revenue and operational efficiency by 320 basis points. Continued investments in research and development were highlighted, with BRL 150 million invested over the last 12 months. The company’s organic revenue grew by 16%, while expanding into Retail, Aesthetics, and Plasma segments, leading to a 60% revenue increase in these areas.
What is Earnings Call?
BLAU3 Profitability Score
Profitability Due Diligence
Blau Farmaceutica SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Blau Farmaceutica SA's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
BLAU3 Solvency Score
Solvency Due Diligence
Blau Farmaceutica SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Blau Farmaceutica SA's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLAU3 Price Targets Summary
Blau Farmaceutica SA
According to Wall Street analysts, the average 1-year price target for BLAU3 is 18.14 BRL with a low forecast of 14.65 BRL and a high forecast of 23.63 BRL.
Dividends
Current shareholder yield for BLAU3 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
Contact
IPO
Employees
Officers
The intrinsic value of one BLAU3 stock under the Base Case scenario is 23.42 BRL.
Compared to the current market price of 14.82 BRL, Blau Farmaceutica SA is Undervalued by 37%.